Clinical applications of 4-factor prothrombin complex concentrate: A practical pathologist's perspective

David Unold, Christopher A. Tormey

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A 4-factor prothrombin complex concentrate (4F-PCC), containing therapeutic doses of Vitamin K-dependent coagulation factors, was recently licensed in the United States for reversal of Vitamin K antagonist therapy. However, given the emergence of several oral anticoagulants for which there are no specific reversal agents, and the existence of many other complex bleeding disorders, it is likely that clinicians will seek to use 4F-PCCs for any number of off-label indications. Thus, the goal of this review is to explore practical issues regarding 4F-PCC, with an emphasis on issues relevant to blood bankers and pathologists. Specifically, our aims are to (1) examine the role of 4F-PCC in Vitamin K antagonist reversal, (2) review its potential use in the treatment of hemorrhage due to novel oral anticoagulants, and (3) explore potential uses in liver disease, trauma-associated bleeding, and rare coagulopathies. Safety and other practical considerations of 4FPCCs will also be discussed.

Original languageEnglish (US)
Pages (from-to)1568-1575
Number of pages8
JournalArchives of Pathology and Laboratory Medicine
Volume139
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Vitamin K
Hemorrhage
Anticoagulants
Blood Coagulation Factors
Liver Diseases
Therapeutics
Safety
Wounds and Injuries
prothrombin complex concentrates
Pathologists

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Clinical applications of 4-factor prothrombin complex concentrate : A practical pathologist's perspective. / Unold, David; Tormey, Christopher A.

In: Archives of Pathology and Laboratory Medicine, Vol. 139, No. 12, 01.12.2015, p. 1568-1575.

Research output: Contribution to journalArticle

@article{3ebc68e428694d49ac70502f7005bdaa,
title = "Clinical applications of 4-factor prothrombin complex concentrate: A practical pathologist's perspective",
abstract = "A 4-factor prothrombin complex concentrate (4F-PCC), containing therapeutic doses of Vitamin K-dependent coagulation factors, was recently licensed in the United States for reversal of Vitamin K antagonist therapy. However, given the emergence of several oral anticoagulants for which there are no specific reversal agents, and the existence of many other complex bleeding disorders, it is likely that clinicians will seek to use 4F-PCCs for any number of off-label indications. Thus, the goal of this review is to explore practical issues regarding 4F-PCC, with an emphasis on issues relevant to blood bankers and pathologists. Specifically, our aims are to (1) examine the role of 4F-PCC in Vitamin K antagonist reversal, (2) review its potential use in the treatment of hemorrhage due to novel oral anticoagulants, and (3) explore potential uses in liver disease, trauma-associated bleeding, and rare coagulopathies. Safety and other practical considerations of 4FPCCs will also be discussed.",
author = "David Unold and Tormey, {Christopher A.}",
year = "2015",
month = "12",
day = "1",
doi = "10.5858/arpa.2014-0366-RS",
language = "English (US)",
volume = "139",
pages = "1568--1575",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "12",

}

TY - JOUR

T1 - Clinical applications of 4-factor prothrombin complex concentrate

T2 - A practical pathologist's perspective

AU - Unold, David

AU - Tormey, Christopher A.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - A 4-factor prothrombin complex concentrate (4F-PCC), containing therapeutic doses of Vitamin K-dependent coagulation factors, was recently licensed in the United States for reversal of Vitamin K antagonist therapy. However, given the emergence of several oral anticoagulants for which there are no specific reversal agents, and the existence of many other complex bleeding disorders, it is likely that clinicians will seek to use 4F-PCCs for any number of off-label indications. Thus, the goal of this review is to explore practical issues regarding 4F-PCC, with an emphasis on issues relevant to blood bankers and pathologists. Specifically, our aims are to (1) examine the role of 4F-PCC in Vitamin K antagonist reversal, (2) review its potential use in the treatment of hemorrhage due to novel oral anticoagulants, and (3) explore potential uses in liver disease, trauma-associated bleeding, and rare coagulopathies. Safety and other practical considerations of 4FPCCs will also be discussed.

AB - A 4-factor prothrombin complex concentrate (4F-PCC), containing therapeutic doses of Vitamin K-dependent coagulation factors, was recently licensed in the United States for reversal of Vitamin K antagonist therapy. However, given the emergence of several oral anticoagulants for which there are no specific reversal agents, and the existence of many other complex bleeding disorders, it is likely that clinicians will seek to use 4F-PCCs for any number of off-label indications. Thus, the goal of this review is to explore practical issues regarding 4F-PCC, with an emphasis on issues relevant to blood bankers and pathologists. Specifically, our aims are to (1) examine the role of 4F-PCC in Vitamin K antagonist reversal, (2) review its potential use in the treatment of hemorrhage due to novel oral anticoagulants, and (3) explore potential uses in liver disease, trauma-associated bleeding, and rare coagulopathies. Safety and other practical considerations of 4FPCCs will also be discussed.

UR - http://www.scopus.com/inward/record.url?scp=84949035422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949035422&partnerID=8YFLogxK

U2 - 10.5858/arpa.2014-0366-RS

DO - 10.5858/arpa.2014-0366-RS

M3 - Article

C2 - 26619030

AN - SCOPUS:84949035422

VL - 139

SP - 1568

EP - 1575

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 12

ER -